| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Product revenues net of discounts and rebates | 437,602 | 100,932 | 163,552 | 135,293 |
| Cost of revenues | 537,690 | 50,051 | 73,272 | 111,687 |
| Gross (loss) profit | -100,088 | 50,881 | 90,280 | 23,606 |
| Research revenues | 90,960 | 206,939 | 92,731 | 12,818 |
| Net (loss) revenue | -9,128 | 257,820 | 183,011 | 36,424 |
| Research and development | 809,777 | 249,884 | 407,622 | 940,063 |
| General and administrative expenses | 1,506,620 | 1,612,764 | 1,686,264 | 1,215,053 |
| Total operating expenses | 2,316,397 | 1,862,648 | 2,093,886 | 2,155,116 |
| Loss from operations | -2,325,525 | -1,604,828 | -1,910,875 | -2,118,692 |
| Interest expense, other | - | - | - | 1,467 |
| Interest expense | 1,708 | 1,221 | 1,790 | - |
| Other operating income (expense), net | - | - | - | 16,623 |
| Change in fair value of derivative liabilities | 21,103 | 140,447 | -5,105 | - |
| Gain (loss) on sale of derivatives | - | - | - | -56,712 |
| Other income, net | 31,550 | 13,066 | 30,322 | - |
| Total interest and other income (expense), net | 8,739 | -128,602 | 33,637 | -41,556 |
| Loss from operations before provision for income taxes | -2,316,786 | -1,733,430 | -1,877,238 | -2,160,248 |
| Provision for income taxes (note 9) | 250 | 1,500 | 63 | 250 |
| Net loss | -2,317,036 | -1,734,930 | -1,877,301 | -2,160,498 |
| Net loss noncontrolling interest | -712 | -1,204 | -752 | -713 |
| Net loss attributed to 60 degrees pharmaceuticals, inc | -2,316,324 | -1,733,726 | -1,876,549 | -2,159,785 |
| Cumulative dividends on series a preferred stock | - | - | 118,158 | 116,571 |
| Unrealized foreign currency translation loss | - | - | -9,904 | 4,403 |
| Net (loss) income - attributed to common stockholders | - | - | -2,004,611 | -2,271,953 |
| Basic (in dollars per share) | -0.66 | -1.25 | -1.56 | -0.93 |
| Basic (in shares) | 3,675,407 | 1,472,891 | 1,283,462 | 2,443,198 |
| Diluted (in dollars per share) | -0.66 | -1.25 | -1.56 | -0.93 |
| Diluted (in shares) | 3,675,407 | 1,472,891 | 1,283,462 | 2,443,198 |
60 DEGREES PHARMACEUTICALS, INC. (SXTP)
60 DEGREES PHARMACEUTICALS, INC. (SXTP)